1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high degree of lipophilicity, novel analogues of 1 with reduced lipophilic character were designed by substituting methylene groups with more polar functional groups in the propylene linker and at the tetralin C4 position. For the chiral analogues, separate enantiomers exhibited substantial and roughly equal affinities within a given receptor subtype, with the greatest difference observed for compound 9 at σ1 (7.5-fold; (-)-(S)-9 Ki=94.6 nM, (þ)-(R)-9 Ki=12.6 nM). Compound (-)-(S)-9 was also found to be the most σ2-selective agent (σ2 Ki=5.92 nM), to possess a lipophilicity consistent with entry into tumor cells (log D7.4 = 2.38), and to show minimal antiproliferative activity. However, (-)-(S)-9 exhibited moderate activity (EC50= 8.1 μM) at the P-gp efflux pump.

Analogues of σ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Added Polar Functionality and Reduced Lipophilicity for Potential Use as Positron Emission Tomography Radiotracers

ABATE, CARMEN rosa;NISO, MAURO;LACIVITA, ENZA;PERRONE, Roberto
2011-01-01

Abstract

1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high degree of lipophilicity, novel analogues of 1 with reduced lipophilic character were designed by substituting methylene groups with more polar functional groups in the propylene linker and at the tetralin C4 position. For the chiral analogues, separate enantiomers exhibited substantial and roughly equal affinities within a given receptor subtype, with the greatest difference observed for compound 9 at σ1 (7.5-fold; (-)-(S)-9 Ki=94.6 nM, (þ)-(R)-9 Ki=12.6 nM). Compound (-)-(S)-9 was also found to be the most σ2-selective agent (σ2 Ki=5.92 nM), to possess a lipophilicity consistent with entry into tumor cells (log D7.4 = 2.38), and to show minimal antiproliferative activity. However, (-)-(S)-9 exhibited moderate activity (EC50= 8.1 μM) at the P-gp efflux pump.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/115468
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 48
social impact